MeSH term
Frequency | Condition_Probility | English Abstract | 3 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Humans | 65 | 0.0 |
Monoamine Oxidase/*genetics | 29 | 42.0 |
Aged | 12 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Dinucleotide Repeats | 2 | 2.0 |
Female | 41 | 0.0 |
Gene Frequency | 6 | 0.0 |
Male | 44 | 0.0 |
Middle Aged | 19 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 36 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
X Chromosome | 3 | 0.0 |
Catechol O-Methyltransferase/*genetics | 6 | 6.0 |
Polymorphism, Genetic | 5 | 0.0 |
Adolescent | 6 | 0.0 |
Adult | 19 | 0.0 |
Autopsy | 3 | 1.0 |
Comparative Study | 4 | 0.0 |
Alleles | 10 | 0.0 |
Cohort Studies | 3 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Genotype | 10 | 0.0 |
Smoking/*adverse effects | 2 | 0.0 |
Exons | 3 | 0.0 |
Introns | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Age of Onset | 3 | 0.0 |
Child, Preschool | 3 | 0.0 |
Genetic Markers | 8 | 0.0 |
Genetic Screening | 2 | 0.0 |
*Linkage (Genetics) | 9 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Clinical Trials | 2 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
X Chromosome/genetics | 3 | 1.0 |
Animals | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Rats | 2 | 0.0 |
*Alleles | 3 | 0.0 |
Parkinson Disease/*genetics | 4 | 4.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Blood Platelets/*enzymology | 3 | 4.0 |
Receptors, Dopamine D2/*genetics | 2 | 0.0 |
Case-Control Studies | 3 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Linkage (Genetics) | 7 | 0.0 |
*Membrane Glycoproteins | 2 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Monoamine Oxidase/genetics | 3 | 13.0 |
DNA Primers/genetics | 3 | 0.0 |
Base Sequence | 11 | 0.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
*Genetic Markers | 2 | 0.0 |
*Genetic Screening | 2 | 1.0 |
Family Health | 5 | 0.0 |
Lod Score | 7 | 0.0 |
Models, Genetic | 2 | 0.0 |
Risk Factors | 3 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
Mental Retardation/*genetics | 3 | 1.0 |
Pedigree | 10 | 0.0 |
X Chromosome/*genetics | 3 | 0.0 |
DNA/genetics | 2 | 0.0 |
Syndrome | 3 | 0.0 |
*X Chromosome | 14 | 1.0 |
Gene Dosage | 2 | 0.0 |
Parkinson Disease/*enzymology/*genetics | 2 | 22.0 |
Biogenic Monoamines/metabolism | 2 | 25.0 |
Restriction Mapping | 3 | 0.0 |
Child | 2 | 0.0 |
Linkage (Genetics)/*genetics | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
DNA | 2 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Infant | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Brain/*enzymology | 3 | 1.0 |
Molecular Sequence Data | 9 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Blindness/*genetics | 3 | 23.0 |
Chromosomes, Human, X/genetics | 2 | 10.0 |
Haplotypes/genetics | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Genes, Structural | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Phenethylamines/*therapeutic use | 2 | 100.0 |
Selegiline/*therapeutic use | 2 | 50.0 |
Double-Blind Method | 2 | 0.0 |
